Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Empowered Funds LLC

Empowered Funds LLC raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1,146.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 37,430 shares of the company’s stock after acquiring an additional 34,427 shares during the period. Empowered Funds LLC’s holdings in Teva Pharmaceutical Industries were worth $1,127,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $25,000. Cornerstone Planning Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after purchasing an additional 755 shares during the period. Allworth Financial LP lifted its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the period. EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in Teva Pharmaceutical Industries by 567.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after buying an additional 1,134 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TEVA shares. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the transaction, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.54% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $35.30 on Friday. The stock has a market cap of $40.59 billion, a P/E ratio of 58.83, a P/E/G ratio of 3.78 and a beta of 0.86. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The stock’s 50 day simple moving average is $33.25 and its 200 day simple moving average is $32.82. Teva Pharmaceutical Industries Ltd. has a 1-year low of $16.08 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.96 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.